(MENAFN- GlobeNewsWire - Nasdaq) Dublin, May 26, 2023 (GLOBE NEWSWIRE) -- The "non-squamous non-small-cell lung cancer in the united states, 2022-2042: cancer populations usa report and data dashboard" report has been added to ResearchAndMarkets.com's offering.
The report provides detailed descriptive epidemiology estimates, forecast out to 20 years, and insights, to support clinical trial design and enrolment, market opportunity assessment and post-marketing authorization activities.
In this report on non-squamous non-small-cell lung cancer (NSq-NSCLC), forecast estimates are provided of incident cases by stage, age and gender, race-ethnicity, anatomical subsite, and PD-1/PD-L1 status. Additionally, the author forecasts those cases each year that become eligible for 1st line treatment for advanced disease, which is further stratified by oncogene driver mutations and amplifications.
Cancer Populations USA is unique in routinely stratifying key cancer populations by race and ethnicity, which can be used to assess the representativeness of clinical trial populations, as well as identify areas of health inequities between different race-ethnicity population groups.
All estimates in this report are based on nationally representative datasets, such as population-based cancer registries, large epidemiological studies and published national population forecasts. Modelled estimates are based on the best practice industry methods to estimate recurrence events and, where required, make imputations and extrapolations.
We provide estimates for the year 2022 and forecast estimates to 2032 and 2042 in the main body of this report. Annualized forecast estimates are provided in supplementary tables at the end of the report, and also in the accompanying data dashboard, if purchased.
Stratification of incident cases by stage is based on the scheme specified by the American Joint Committee on Cancer (AJCC) 8th edition. Due to small numbers, some stage groups have been aggregated in this report. Wherever possible, this has been into meaningful groupings based on recommended clinical practice (NCCN, 2023).
Our forecast model uses a proprietary algorithm taking account of historical trends, long-term evolution - at the age- and gender-specific level within each race-ethnicity group - in the size and composition of the national population at risk, and inter-generational trends in exposures to both known and unknown risk factors. In addition to national estimates, the publisher also estimates the state-specific size of key populations for the year 2022 for almost all US states, and Puerto Rico, with corresponding heat maps and tabulated results.
All of the key populations included in the report are also reported for each year of the forecast period, along with interactive tables, patient journey diagrams and heat maps, in the accompanying data dashboard.
Purchase of the report and dashboard comes with 12 months client support, with guaranteed response to client queries within 1 working day. The Cancer Populations USA report series is available for a wide range of tumors, both solid tumors and hematological malignancies. Similar reports can be provided for other indications (including non-oncology indications), or for other country(s).
Key Topics Covered:
2. Summary of results
3. Newly diagnosed incident cases
4. Advanced 1st line drug-treatable cases
5. Tumor genetics and biomarker expression
6. State-level epidemiology
7. 10 and 20 year epidemiological forecasts
8. Detailed methods
9. National population projections
11. Supplementary data tables
12. Additional support
13. Further information
For more information about this report visit
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Tags lung cancer oncology solid tumor tumor
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.